Replies to post #97388 on PharmaCyte Biotech Inc (PMCB)

[DragonBear]

RenovoRX sounds promising… but....

Ciab is for people who don’t benefit from this combination and there are many of them

No. The Kenny wonder treatment will be limited to mythical 2nd line testing, using just Ifosfamide. Assuming the mythical CT ever occurs. But that's it. The Kenny wonder treatment is limited to Ifosfamide, or other alkylating drugs such as Cytoxin. The RenovoRX system is far more flexible. It doesn't have to rely on a drug becoming activated by magic cells. And it's applicable to 1st line therapy. Likely more economical to produce.

RenovoRX is currently trying to show efficacy as a 1st line treatment. They are starting with nab-paclitaxel and gemcitabine injected locally via the catheter after initial induction with nab-paclitaxel and gemcitabine + radiation. Later they could add drugs designed to disrupt the stromal layer, and even add immunotherapy directly to the site. There may be in the future no need for a 2nd line rescue therapy.

The triggering by ciab is right by the tumor whereas renoxo will be pancreas wide

You have it backwards. CIAB are individual beads. It's not a semi-permiable mesh stretch across the width of a pancreatic artery. Blood is free to flow past the beads, or flow through the beads by random collision, and then flow through the pancreas, without ever hitting a cancer cell. There's no magnetic attraction between the beads and Ifosfamide. Neither is Ifosfamide preferentially attracted to cancer cells. It enters a cell be it cancer or not by diffusion. The RenovoCath is inserted into a tumor vein, or closest vein to the tumor. The drugs are held in place, with the vein blocked, and are not free to flow in the blood stream initially. They must first diffuse from the catheter to the surrounding cells, and eventually find their way out of the pancreatic via another blood flow.

So ciab is more targeted and less destructive of other dividing cells

First CIAB is not a drug. Ifosfamide is the drug. And it will alkylate the DNA of any cell it diffuses into. If a cell is in the process of dividing in the presence of Ifosfamide, it will soon be dead. As with any other chemo drug.

If those combos have already failed for a patient they will surely prefer a side effect free treatment like ciab.

Except CIAB+Metronomic Ifosfamide is not side effect free. Also, it's a game of time. If the RenovoRX system guarantees 2 yrs, and later added targeted pathway drugs add another 1-2 yrs, then it's quite possible with immunotherapies emrging, a cure in the next 5 yrs will be possible. There are drugs in late testing that will disrupt the tumor growth, making it more susceptible to chemo, and have no side effects.

I think in late stage inoperable ciab still has many advantages over renoxo.

Thinks have nuttin to do with it. What specific advantage does Ifosfamide have, over the other drugs? And why isn't it a first line drug, or add on drug, for first line inoperable patients?

Another thing to think of is: Why isn't CIAB+Metronomic Ifosfamide being tested as a front line treatment? Remember that was the initial scam line PR pump by Kenny. Is it because it's too expensive as Kenny claims, or because the FDA refused to allow it to be tested as a front line treatment? Knowing it would be inferior to current front line treatments. Instead one ends up with a 2nd line mythical CT, that currently has no funding. Still seems "too expensive" doesn't it?

Also note Renovo with a 5 yr lead will be first to market. RenovoCath won't be replacing CIAB, because CIAB will not exist in the market. However, it's correct to state CIAB will not replace RenovoCath. CIAB is likely never to get past a mythical Phase 1 CT. Based on the tumor growth seen in the ad hoc studies of 1999 at 20 weeks, the mythical CT will be lucky to get past 6 months.

And renoxo has no upside with ascites or diabetes or cabbinoids does it

Both Renovo & PMCB have no upside in those 3 areas. Although for ascites, at least the separate induction component for RenovoCath of a 1st line PC therapy with systemic drugs, would help to keep metastasis leading to ascites under control.

Also how do you make money from renoxo as it’s difficult to commercialize

It's extremely easy to commercialize. Offering to manufacture the catheter for other biotech/pharma companies interested in trying the approach with their drugs.

Where’s the patent that can protect an already established way of delivery?

Indeed, where is the published patent for CIAB? The AN patent expired. Now one has Kenny trying to "renew" the same patent. The USPO has yet to grant it. Why do generic drugs exist? Answer: Because the patent expired. There is no patent for CIAB is there?

Haven't checked, but presumably RenovoCath has a patient applied to it. Most important it has been approved as a device by the FDA. A competitor could probably come up with their own, but would have to wait for FDA approval.